{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Pancreatic+Cancer&page=5", "query": { "condition": "Stage IB Pancreatic Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Pancreatic+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Pancreatic+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T00:59:37.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02077933", "title": "Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Breast Neoplasms", "Kidney Neoplasms", "Pancreatic Neuroendocine Neoplasms (pNETs)" ], "interventions": [ { "name": "alpelisib", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2014-05-14", "completion_date": "2019-04-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • New York, New York", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02077933" }, { "nct_id": "NCT01420874", "title": "Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Cancer of Pancreas", "Pancreatic Neoplasm", "Malignant Neoplasm of Large Intestine", "Malignant Tumor of Colon", "Colon Carcinoma", "Cancer of Colon", "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFOX6", "type": "DRUG" }, { "name": "EGFRBi armed ATC Infusions", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2011-08-17", "completion_date": "2020-10-19", "has_results": false, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420874" }, { "nct_id": "NCT02048943", "title": "Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dovitinib lactate", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-01-09", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02048943" }, { "nct_id": "NCT03337087", "title": "Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Biliary Tract Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-11-02", "completion_date": "2025-08-09", "has_results": true, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03337087" }, { "nct_id": "NCT04890613", "title": "Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CX-5461", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Senhwa Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-09-08", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 6, "location_summary": "Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04890613" }, { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" }, { "nct_id": "NCT03889795", "title": "Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Danae Hamouda, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-06-05", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03889795" }, { "nct_id": "NCT01192763", "title": "RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 6, "location_summary": "Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01192763" }, { "nct_id": "NCT05251038", "title": "Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Unresectable Pancreatic Cancer", "Metastatic Pancreatic Cancer", "KRAS P.G12C" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Liposomal Irinotecan (nal-IRI)", "type": "DRUG" }, { "name": "5 Fluorouracil (5FU)", "type": "DRUG" }, { "name": "Leucovorin (LV)", "type": "DRUG" }, { "name": "Gemcitabine (GEM)", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Devalingam Mahalingam", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09-13", "completion_date": "2023-01-31", "has_results": false, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05251038" }, { "nct_id": "NCT02178436", "title": "Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mohammed Najeeb Al Hallak", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2014-10-31", "completion_date": "2023-04-05", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-06T00:59:37.495Z", "location_count": 2, "location_summary": "Detroit, Michigan • Stony Brook, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178436" } ] }